Robert Wood Johnson University Hospital (RWJUH) is an example of a hospital that transformed its laboratory into a profit-making center by offering laboratory outreach services and optimizing the operations of the laboratory. Additional details on RWJUH and the innovative profit center laboratory are included below and in the attached Google Slide.
To offer an innovative laboratory outreach program, RWJUH contracted XIFIN to build the analytics-driven lab using XIFIN RPM, which provides full visibility and insights into the financial performance of all lab operations at every stage.
These data points enable the executives at RWJUH to evaluate the lab's operating performance, show profitability, identify areas requiring improvement, negotiate contracts, and provide critical data for making the best business decisions.
Your research team searched through medical reports, health care companies' press releases, and general health news articles and reportstofind information regarding the case study included above. Importantly, we came across a press release by XIFIN regarding its commitment to building an innovative analytics-driven laboratory system for RWJUH to transform RWJUh's lab from a cost center to a profit center. Next, we expanded our search by looking for more in-depth data regarding this case study. On that note, additional findings were pulled from 365 HIMSS and Recycle Intelligence. Other company data were unearthed from the RWJUH website. In the attached Google Slide, we have included a recent commercial video promoting the hospital's products and services.
10 Types of Innovation - Network Innovation
Northwell Health is an example of a health care facility that has experienced success by leveraging partnerships with other companies, as shown by its recent creation of "The Fin," which unified clinical care, aerospace, 3D printing, and prosthetics expertise within Northwell Health and outside partners to create a breakthrough product. Additional details of Northwell Health's location, business model, and its innovation are summarized below and in the attached Google Slide.
Northwell Health is a New York-based health care provider committed to providing innovative, quality health care to its communities through coordinated clinical care, community health, medical research, and medical technology development.
Dedicated to providing unique health care solutions to the communities it serves, Northwell Health identified a need for amphibious prosthetics, or prosthetics that enable individuals with missing limbs to swim.
Partnership Innovations to Provide a Unique Solution to Amputees
Upon identifying the gap in prosthetic limbs that enable swimming capabilities, Northwell Health collaborated with Veteran Dan Lasko, an amputee, as a development partner to better understand the problem and to identify possible solutions.
To solve this problem, Northwell Health leveraged the expertise from 3D printing expert, Tom Goldstein, with The Feinstein Institute, as well as expertise from other prosthetics, aerospace, and 3D printing firms including Eschen Prosthetics, The Composite Prototyping Centre, and Markforged 3D Printing, as well as Northwell's commercial firm, Northwell Ventures.
The internal collaboration across Northwell Health's clinical, medical research, and commercial arm alongside external collaboration with its network partners resulted in the creation of "The Fin," which was rolled out in a pilot clinical trial in 2017, to allow for amputees to more easily transition from walking on land to swimming in water without hindrance from their prosthetic limbs.
Northwell Health hopes to partner with the U.S. Department of Veterans Affairs in the future to roll-out this amphibious prosthetic on a larger scale, in an effort to support the 1.9 million Veterans returning from deployment with a missing limb.
Northwell Health's unification of experts and resources across clinical care, prosthetics, aerospace, and 3D printing created a prosthetic that was the first of its kind and expanded Northwell Health's capabilities in Veteran care.
Results of the Innovation
The campaign advertising The Fin resulted in 32 million impressions and won two Lions awards: a silver Lion in the Pharma category for Patient Engagement Utilities, and a bronze Lion for Product Design for Medical Devices.
Beyond award recognition, Northwell Health's social media mentions increased by 548% and received 4.9 million in earned media as a result of the campaign for The Fin.
The health care provider also successfully impacts the health of the communities it serves, contributing over $1.3 billion in community benefit through community health programs and health professional training.
The research team began its search for case study examples of network innovation within the pharmaceutical or health care space by first searching a case study database, such as WARC, for recent examples within the last three years. The research team was able to identify Northwell Health as a recent case study example through searching WARC's database, filtering by "Pharma & Health Care" categories, filtering results within the last three years, and filtering results to show only case studies. While WARC's case study for Northwell Health was not accessible due to its paywall, the research team was able to locate additional sources from marketing research and news sites (e.g., PR Newswire, J. Walter Thompson, Econsultancy) to further detail the innovation.
10 Types of Innovation - Structure Innovation
Maxima hospital in partnership with Phillips implemented an adaptable room concept and integrated patient monitoring to deliver personalized service and comfort for its women and infant patients at its Woman-Mother-Child Center. The innovative concepts involved the reorganization of talent and departments across prenatal, delivery, postnatal, breastfeeding support, and discharge services to serve in one room. We attached here a video presentation of the innovations in addition to presenting the findings in a Google Slide here.
Maxima Hospital launched its Woman-Mother-Child Center, in partnership with Philips, where it implemented innovative concepts including adaptable room concept and integrated patient monitoring that involved the restructuring of prenatal to postnatal care to center on the patient rather than operate as independent units.
Among the innovative policies at Maxima Hospital include the Sacred Hour policy where babies stay with their mother for the first hour after birth. The policy has resulted in babies crying much less in the first hour after birth, improved breastfeeding, and higher patient satisfaction from being included in early infant care.
Philips has adapted the light and sound in the Woman-Mother-Child center to suit the day-night rhythm and needs of newborns. It supports mothers with interactive light animations.
Increased patient satisfaction due to closer contact with their babies and family has improved the work environment for nurses resulting in more enjoyable work.
A video presentation of the impact of the implementation of the innovative concepts of adaptable room concept and integrated patient monitoring can be found here.
In order to determine a case study example of a pharmaceutical or health company that has successfully innovated by identifying new ways of structuring itself or reorganizing talents and assets to create value, your research team reviewed news and industry sources such as Forbes and Deloitte. Importantly, your research team sought to identify a global case study of innovations that had taken place over the last five years in the pharmaceutical and health industries. Critically, we identified how the innovations in restructuring resulted in creating value. We identified a video on the innovations and attached it to our report. Additionally, we presented our findings in the attached Google Slide.
10 Types of Innovation - Process innovation
Eli Lilly and Company is an example of a pharmaceutical company that has experienced success by optimizing its drug manufacturing process. The company built the industry's first multi-product small volume continuous drug manufacturing facility in Kinsale, Ireland. Operators' exposure to toxic components is one of the problems that have been solved by the facility's innovative use of Continuous Manufacturing. Additional details of Eli Lilly and Company's location, overview, and its innovation are summarized below and in the attached Google Slide.
Founded in 1876, Eli Lilly and Company is an American pharmaceutical company with headquarters in Indianapolis, Indiana. Its products are marketed in 120 countries.
The human pharmaceutical business segments sells medicines which are developed by the company's scientists. On the other hand, the animal health business segment develops, manufactures, and markets products for food animals and companion animals.
The Process Innovation
When making drugs that require the use of highly toxic components, Lilly wanted to minimize the operators' exposure to toxic components, reduce the time involved in manufacturing drugs, and decrease the overall cost.
In the traditional batch process drug manufacturing, the different chemical reaction and purification steps are done in large costly vessels. This can be uneconomical when very small amounts of drugs are needed during the early stage clinical trials.
In 2015, Lilly built a multi-product small volume continuous drug manufacturing facility in Kinsale, Ireland. The factory uses continuous manufacturing.
This facility enabled the multiple steps involved in the manufacturing of drugs to happen simultaneously, reducing the time required to manufacture the drugs. It was designed to manufacture the entire process steps continuously for the quick delivery of Active Pharmaceutical Ingredients (API) to meet patients' needs.
This was the first facility of its kind in the pharmaceutical industry and gave unprecedented responsiveness to medical needs. It allowed Lilly to provide a more reliable supply of medicine to patients. Lilly was the only company that could manufacture multiple Good Manufacturing Practice synthetic steps simultaneously using the technology.
The innovation was labeled as an important milestone in the continuous manufacturing of pharmaceuticals.
The facility enhanced Lilly's (Small Volume Continuous) SVC platform and enabled the launch of new medicines to the market. Included process design concepts also advanced the company in process analytical technologies and advanced automation.
The SVC facility reduces the manufacturing time by the flexible, modular nature of the equipment. It can produce drugs in a week after starting to feed and consume the starting materials.
The processes used by the facility introduce a change in process and operator safety. From the operator viewpoint, the equipment is small and the process is covered in fume hoods, reducing the potential exposure to hazards. Small quantities of solvents, catalysts, and hazardous materials are also used at the same time, which creates a shift in process safety management.
The innovation has led to an API cost reduction of 50%, a decrease in technical transfer time, and a reduction of waste through the integration of green chemistry.
Because of the innovation, Eli Lilly and Company was named as the 2019 Facility of the Year (FOYA) process innovation category winner by the International Society of Pharmaceutical Engineering.
The company won because it displayed exemplary application of novel process manufacturing techniques in the new facility. These include fundamental scientific processing approaches and related applied science-based solutions to existing and new challenges in the pharmaceutical industry.
Interesting Background Facts About the Company
Lilly was the first company to mass produce the polio vaccine and have an approved biosimilar insulin product in the US.
Lilly was among the first companies to develop a method for mass production of Penicillin-G. This was the world's first widely available antibiotic, which marked the start of the sustained effort to fight infectious diseases.
A Video Presentation
Here is a video presentation on Lilly's YouTube channel related to research and development.
10 Types of Innovation - Product Performance Innovation
XRHealth is a healthcare startup that was established in 2016. It is a leader in therapeutic applications and extended reality. The company's VR health platform allows healthcare providers to easily collect and access patient information. Patients can use its VR headset during rehabilitation. The company works with healthcare centers like Mass General Hospital’s Sports Medicine Center and has partnered with companies like Healium. A detailed analysis of the company's offerings, innovation, and location can be found in this Google Slide.
Eran Orr, its CEO, established the company after "experiencing long rehabilitation processes." He founded XRHealth with the belief that the XR technology (VR/AR/MR) will change healthcare as we know it.
XRHealth partners with healthcare providers to implement virtual reality in patients' rehabilitation process. Patients with any form of painful or difficult procedures are offered VR glasses to minimize stress and take their mind off the pain.
This technology allows for a more positive patient experience while also forging a better environment for healthcare providers to perform any painful procedures safely.
XRHealth's virtual reality technology also helps healthcare centers gather new patient information and share treatment instructions after the patient is sent home.
In addition, the company offers other custom VR/AR solutions tailored exclusively for the needs and characteristics of any healthcare company.
So far, XRHealth has raised over $8 million in more than three finding rounds from investors like MassChallenge, 20/20 Healthcare Partners, Plug & Play Accelerator, TiE Boston, Hatchery Ventures, and ScaleUp.
It had two crowdfunding rounds in 2017 where it raised roughly $2 million. In August 2017, it had a seed round where it raised $3.25 million.
The company uses Rift and Oculus Go to offer VR technology solutions for a wide range of health challenges, "from pain management for birthing mothers and cancer patients during chemotherapy to alleviating patient anxiety before and after surgery."
In July 2019, XRHealth opened its platform to third party developers. This decision was made to create more robust VR healthcare experiences. A remarkable partnership through the open platform is Healium, which allows "patients to see and power VR technology through their emotions."
XRHealth has collaborated with several companies, including Magic Leap, Sheba Medical Center, and Allscripts, among others.
This video describes how VRPhysio can be beneficial.
This one minute video was on XRHealth's website. It analyzes how its platform can be used and how patients are using its virtual reality service.
10 Types of Innovation - Product System Innovation
Otsuka Pharmaceutical has successfully innovated its product system through digital medicine technology to help solve medication non-adherence among mental health patients. These are outlined below and in the attached Google Slides.
Otsuka Pharmaceutical Companies (U.S.)
Otsuka US consists of Otsuka Pharmaceutical Inc. which commercializes drugs and Otsuka Pharmaceutical Development & Commercialization which develops healthcare products.
One healthcare business that successfully implemented a service innovation is GuideWell Connect. They started making high-touch phone outreaches to patients who are most likely to use emergency rooms repeatedly. Thanks to this, they helped Florida Blue, a health plan provider with whom they share a parent company (GuideWell), lower their costs, as well as improve their members' healthcare experience and decrease their out-of-pocket spendings. The attached presentation has been filled with the requested details.
GuideWell Connect provides tech-enabled consumer engagement services to help health plans manage member relationships. Thanks to their solutions, their clients can improve their financial results and health outcomes for the patients, as well as increase membership.
The company is located in Jacksonville, Florida, United States.
Both one of GuideWell Connect's partners, Florida Blue, and the members of its plan struggled with high costs, which were a direct result of overcrowded Emergency Rooms. According to the company, one of the reasons was that the patients were not aware of more efficient and affordable options, such as urgent care facilities or primary care physicians.
To solve the issue, GuideWell Connect's member engagement team started uncovering members that either have been frequent visitors to ER rooms or had the potential to become ones. Then, they started educating those members on other options to receive medical help through high-touch phone outreaches.
They informed members about the availability of the Nurse Advise Lines. Also, they presented the capabilities and advantages of urgent care centers, which include saving time and money.
Additionally, the company educated patients on the importance of having a good relationship with their primary care physician, which can help discover and treat health issues early.
After making more than 105,000 high-touch phone outreaches with a 30% contact rate, GuideWell Connect helped their partner health plan to save almost a million $, as well as lowered the costs for the members and showed them how to get better healthcare.
In 2018, the innovation received a Gold Stevie Award. Those awards are given to companies that demonstrate exceptional sales or customer service.
Interesting Facts About the Company
GuideWell Connect's parent company, GuideWell, has also been recognized for its healthcare service innovation, with its Chief Strategy Officer being a speaker at the Conference Board’s Innovation Master Class and describing it.
GuideWell Connect has a customer satisfaction score of 92%.
The company is one of the partners approved to use Enhanced Direct Enrollment, a federally-facilitated "pathway for consumers to enroll in health insurance coverage."
Earlier this year, the company acquired a provider of a member engagement platform, Onlife Health.
A Video Presentation
Here is an example of a YouTube ad video created by the firm, related to its exceptional customer service.
We started searching for examples of pharmaceutical or health companies that have successfully innovated by identifying new ways of improving the utility, performance, and apparent value of an offering in academic databases, such as ScienceDirect or the National Center for Biotechnology Information. We assumed that since they often cover healthcare innovations that can influence patients' wellbeing, they may also focus on service innovations specifically. While we identified multiple examples of service innovations by healthcare companies, such as those provided here and here, it was impossible to find relevant video presentations.
Next, we searched YouTube to find specific examples of ads that promote service innovations by healthcare companies. We thought that it might be possible to find videos of companies speaking about their improved offerings to explain them to the generalpublic. However, the only relevant and up-to-date video we found explained the service innovation by GuideWell. Unfortunately, it didn't target the generalpublic, but the participants of the innovation conference.
Lastly, we scoured through healthcare and business media, including websites like Forbes, Business Insider, as well as healthcare sections of CNBC and the New York Times. We also looked into databases of business and healthcare-related awards, like Stevie Awards. We hoped that one of those sources would provide us with a success story of a healthcare or pharmaceutical company that achieved success through service innovation. While we found a relevant example of GuideWell Connect, the videos we uncovered were a little too long. Also, while they promote the company's offerings related to the innovation (such as analyzing consumer's needs and educating them), they don't focus on this specific innovation.
10 Types of Innovation - Channel Innovation
Teva Pharmaceutical successfully innovated its distribution channel for Copaxone by establishing a network of specialty pharmacies integrated into a patient support program. This program is called Shared Solutions®. These findings are outlined below and in the attached Google Slides.
Teva Pharmaceutical is a global pharmaceutical company that develops both generic and specialty drugs in nearly all therapeutic areas.
The company is headquartered in Petah Tikva, Israel and has also established its presence in 6 locations around the world including the US and Europe.
Teva specializes in both specialty and generic medicines, respiratory drugs, biologics, biosimilars, pain care and others.
Sunovion is a Massachusetts-based pharmaceutical company that focuses on developing therapies for people who are suffering from serious neurological, psychiatric, and respiratory conditions. To increase brand awareness, the company took advantage of sponsoring medical congresses, as well as launching a multichannel marketing strategy, where it exposed the brand to the key stakeholders of the industry. Detailed below is a brief background of the company and how it successfully improved product recognition and branding. The requested information has also been entered in the Google Slide attached.
Company Innovation on Product Recognition & Branding
Due to competition from the generics market, competing marketing channels, reduced budget, and regulatory restrictions in prescription drug promotions, pharmaceutical companies, including Sunovion, are abandoning the traditional product-based campaigns and are instead focusing on value-based strategies.
Its multichannel marketing strategy includes digital initiatives to communicate information about the diseases, as well as the brands that target such diseases, to the industry's key stakeholders: healthcare practitioners, patients, and caregivers.
The company also sponsored two prominent neurology-focused annual medical congresses, the American Epilepsy Society (AES) and the American Academy of Neurology (AAN). In these sponsorships, Sunovion put its name on everything to increase brand awareness, from exhibit ads to programs and booklets to transportation services to water fountains and cellphone charging stations.
Results of the Product Recognition & Branding Initiatives
The company's new website, which was launched as part of their multichannel marketing strategy, was a finalist for the 2016 Best Branded Website for Healthcare Professionals at the Medical Marketing & Media Awards.
Aside from these awards, Aptiom's net sales in North America grew 70.4% in 2016 compared to its 2015 figures. The sales of its drug for chronic obtrusive pulmonary disease (Brovana) and its schizophrenia drug (Latuda) also showed a significant increase of 28% and 24.8%, respectively.
Interesting or Little Known Background Facts about Sunovion
Sunovion Answers—a support experience provided by the company to answer questions about insurance benefits, savings options, Sunovion medications, and online resources and advocacy groups—has been recognized as a provider of Outstanding Customer Service Experience for Phone Support by JD Power.
Sanofi is a major global pharmaceutical company that has successfully innovated its consumer engagement by using sarcasm and comedy to reach local Middle East audiences. These are outlined below and in the attached Google Slides.
Sanofi is a global pharmaceutical company and a major player in different drug markets including oncology, immunology, diabetes, vaccines and rare diseases among others.
The company is headquartered in Paris, France but has established its presence in 11 locations around the world including the US, Asia, South Africa and the Middle East.
"In November 2017, the FDA announced its approval for the first time of an existing drug that will utilize a digital ingestion tracking system: Abilify MyCite (aripiprazole tablets with sensor)"
"The Abilify MyCite system, distributed and marketed by Otsuka America Pharmaceutical, Inc., is a drug-device combination product consisting of aripiprazole tablets embedded with an ingestible event marker (IEM) sensor; a MyCite wearable sensor patch that detects the signal from the IEM sensor after ingestion and transmits data to a smartphone application; a MyCite app (a smartphone application used to display information to the patient); and a Web-based portal for healthcare professionals and caregivers for the purpose of tracking drug ingestion and adherence."
"Abilify MyCite is indicated for the treatment of schizophrenia in adults, the acute treatment of manic and mixed episodes associated with bipolar I disorder in adults, and adjunctive treatment of major depressive disorder in adults."
" A sensor embedded in the Abilify MyCite tablet records that the medication was ingested, sending a message from the tablet’s sensor to a wearable patch, which then transmits the information to a mobile application.
The patient can track their adherence on a smartphone and also give permission to their caregivers and/or clinician to access the information through a Web-based portal."
"Although digital medicine may not require clinicians to utilize patient data, it may become an expectation of both patients and insurance carriers. "
"Historically, poor adherence to prescribed medication regimens negatively affects health outcomes, resulting in disease progression, increased hospitalizations, and patient fatalities—all of which impact overall healthcare costs in the United States."
"In September 2015, the Food and Drug Administration accepted the first digital medicine new drug application for a drug-device combination of Otsuka’s Abilify® (aripiprazole) and an ingestible sensor embedded in the tablet that digitally records ingestion."
"When this digital medicine is taken, it sends a signal to a patch worn by the patient. The information is recorded, time-stamped, and relayed to any Bluetooth-enabled device and, with patients’ consent, to their physicians and/or their caregivers. "
"An encapsulation model in which a tablet is co-encapsulated with the ingestible sensor has been successfully used in the setting of renal transplant, diabetes, hypertension, and hypercholesterolemia."
" This technology can serve as a tool to measure and identify nonadherence. Having this information in real time and sharing it with health care providers can play a role in developing better communication and counseling interventions."
"The Abilify® (aripiprazole) digital medicine introduces a novel technological method for measuring medication adherence that provides real-time feedback to patients and health care providers allowing for timely interventions."
"The technology could potentially be used to monitor whether post-surgical patients took too much opioid medication or clinical trial participants correctly took drugs being tested."
"Insurers might eventually give patients incentives to use them, like discounts on copayments, said Dr. Eric Topol, director of Scripps Translational Science Institute, adding that ethical issues could arise if the technology was “so much incentivized that it almost is like coercion.”"
"Another controversial use might be requiring digital medicine as a condition for parole or releasing patients committed to psychiatric facilities."
"The newly approved pill, called Abilify MyCite, is a collaboration between Abilify’s manufacturer, Otsuka, and Proteus Digital Health, a California company that created the sensor."
"Asked whether it might be used in circumstances like probation or involuntary hospitalization, Otsuka officials said that was not their intention or expectation, partly because Abilify MyCite only works if patients want to use the patch and app."
"Otsuka also made an $88 million investment as part of the expansion. The companies plan to launch Abilify MyCite, approved in November 2017, by the end of this year."
"A collaboration between a Japanese drugmaker and a US company responsible for the first Food and Drug Administration-approved pill to include a digital sensor to track ingestion are expanding their partnership."
"Redwood City, California-based Proteus Digital Health and Otsuka Pharmaceutical Co. – which is based in Japan but also has operations in Princeton, New Jersey – said Thursday that they would expand their global collaboration to deepen their relationship and expand development and commercialization of medicines that include Abilify MyCite and others over the next five years. "
"The pill is one way to address the prevalent problem of patients not taking their medication correctly, with the IMS Institute estimating that the improper and unnecessary use of medicine cost the US healthcare sector over $200 billion in 2012."
"The approval also opens the door for pills that are used for other conditions beyond mental health to be digitized."
"The Wall Street Journal reports that the FDA is anticipating a potential raft of approval requests for other digital pills. "
"Teva established specialty pharmacy distribution networks through its Shared Solutions program to reduce friction across the therapy decision making process and to support Copaxone compliance.9
The program provides patient and provider support resources through Teva’s online portal, nurse hotline and specialty pharmacy providers.9"
"Since losing patent exclusivity of its blockbuster Multiple Sclerosis drug, Copaxone, in 2015, Teva Pharmaceuticals has lost over $50B in market cap. "
"Teva pursued multiple strategies to mitigate the impact from Copaxone generic entrants upon loss of exclusivity. "
"These strategies, outlined at Teva’s 2012 investor meeting, included (1) expanding its pipeline of higher margin branded therapies, (2) focusing on its biosimilar therapy pipeline, and (3) improving global supply chain efficiency. "
"Common across of these initiatives is the increasing use of “digitization” to drive efficiency and value for the organization."
"Benefits Investigation. We can perform an investigation into your pharmacy benefits plan in order to determine the most convenient way for you to receive COPAXONE®."
"Co-pay Assistance. You may qualify for COPAXONE Co-Pay Solutions®. If you are eligible for this program, you can take advantage of lower co-pays for COPAXONE® 40 mg, which could bring your out-of-pocket expenses down to $0.* Terms and conditions apply."
"Benefits Specialists. We have a team of dedicated Benefits Specialists to take your call, work with you to navigate coverage concerns, and help you understand your insurance plan as it relates to Teva’s COPAXONE®."
"Teva Pharmaceuticals has been developing and producing medicines to help improve people’s lives for more than a century. We are committed to being a global leader in generic and specialty medicines with a portfolio of 3,500 products in nearly every therapeutic area."
"Type Public Company
generic medicines, specialty medicines, CNS, active pharmaceutical ingredients, respiratory, biosimilars, biologics, pain care, migraine, and oncology"
Interact with the map to explore all locations"
"Sanofi and their digital agency, Eureka Digital, have been keeping it a bit more comedic with two of their main pages. Maalox and Novaldol have been leading the pack with their own separate brand of light and sarcastic captions."
"When Maalox talks, it talks Comedy
At 269K fans, this antacid medicine has been focused on relatable posts with a tinge of comedy. The Facebook page’s engagement rate between Nov. 2017 and 2018 is 86.3%, with an average 2.97% per post."
"Their pain-killer, Novaldol, leans more into our favorite engagement theme, Sarcasm. Using this focus, the brand has been able to grab a 121.2% Facebook page engagement rate, with an 8.6% per post. "
"Sanofi’s other half is all about being the doctor or advice giver, starting with Telfast. With this antihistamine over the counter med, the pharmaceutical company leans towards a more consumer-centered informatic social style."
"The brand must be doing something right, with their Facebook page handling an engagement rate of 421.46% between Nov. 2017 and 2018, alongside 6.58% engagement per post."
"Balancing between being part of a serious industry and engaging social media users is tough for pharmaceutical products."
"Sanofi is a global life sciences company committed to improving access to healthcare and supporting the people we serve throughout the continuum of care.
From prevention to treatment, Sanofi transforms scientific innovation into healthcare solutions, in human vaccines, rare diseases, multiple sclerosis, oncology, immunology, infectious diseases, diabetes and cardiovascular solutions and consumer healthcare. "